An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

A Phase 2a Study of BMS-790052 and BMS-650032 in Combination Therapy With Japanese Subjects With Genotype 1 Chronic Hepatitis C (HCV) Virus Infection

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221067

Enrollment

Registered

2010-04-14

Start date

2010-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Interventions

investigational material(s) Generic name etc : BMS-790052, BMS-650032 INN of investigational material : Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of more than 5logIU/mL (100,000 IU/mL) at screening

Exclusion criteria

Exclusion criteria: Subjects with evidence of liver cirrhosis Evidence of HCC Co-infection with hepatitis B virus, HIV

Design outcomes

Primary

Measure	Time frame
To assess safety and tolerability, as measured by related serious adverse events (SAEs) and discontinuations due to related AEs. To determine the proportion of subjects who achieve SVR12.	—

Secondary

Measure	Time frame
The proportion of subjects who achieve RVR The proportion of subjects with extended rapid virologic response The proportion of subjects who achieve SVR24 Resistant variants associated with clinical failure	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026